ST未名获得一类创新药重组人神经生长因子SMR001滴眼液III期临床试验伦理批件

Core Viewpoint - ST Unimed (002581.SZ) announced that its wholly-owned subsidiary, Shandong Yandu Biotechnology Co., Ltd., has received ethical approval for the Phase III clinical trial of its innovative drug, recombinant human nerve growth factor SMR001 eye drops, for the treatment of moderate to severe dry eye syndrome [1] Summary by Categories Clinical Development - The ethical approval from the Ethics Committee of Beijing Tongren Hospital, affiliated with Capital Medical University, allows the project to officially commence [1] - The approval signifies that the project has a compliant ethical foundation for conducting clinical trials [1] Financial Impact - The short-term impact on the company's operating performance is not expected to be significant due to the nature of the clinical trial approval [1]